Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital, Yokohama 224-8503, Kanagawa, Japan.
Nonprofit Organization, Kanagawa Spine Research Society, Isehara 259-1193, Kanagawa, Japan.
Medicina (Kaunas). 2022 Sep 15;58(9):1284. doi: 10.3390/medicina58091284.
Background and Objectives: Intradiscal injection of Condoliase (chondroitin sulfate ABC endolyase), a glycosaminoglycan-degrading enzyme, is employed as a minimally invasive treatment for lumbar disc herniation (LDH) and represents a promising option between conservative treatment and surgical intervention. Since its 2018 approval in Japan, multiple single-site trails have highlighted its effectiveness, however, the effect of LDH types, and influences of patient age, sex, etc., on treatment success remains unclear. Moreover, data on teenagers and elderly patients has not been reported. In this retrospective multi-center study, we sought to classify prognostic factors for successful condoliase treatment for LDH and assess its effect on patients < 20 and ≥70 years old. Materials and Methods: We reviewed the records of 137 LDH patients treated through condoliase at four Japanese institutions and assessed its effectiveness among different age categories on alleviation of visual analog scale (VAS) of leg pain, low back pain and numbness, as well as ODI and JOA scores. Moreover, we divided them into either a “group-A” category if a ≥50% improvement in baseline leg pain VAS was observed or “group-N” if VAS leg pain improved <50%. Next, we assessed the differences in clinical and demographic distribution between group-A and group-N. Results: Fifty-five patients were classified as group-A (77.5%) and 16 patients were allocated to group-N (22.5%). A significant difference in Pfirrmann classification was found between both cohorts, with grade IV suggested to be most receptive. A posterior disc angle > 5° was also found to approach statical significance. In all age groups, average VAS scores showed improvement. However, 75% of adolescent patients showed deterioration in Pfirrmann classification following treatment. Conclusions: Intradiscal condoliase injection is an effective treatment for LDH, even in patients with large vertebral translation and posterior disc angles, regardless of age. However, since condoliase imposes a risk of progressing disc degeneration, its indication for younger patients remains controversial.
椎间盘内注射 Condoliase(软骨素 ABC 内切酶),一种糖胺聚糖降解酶,作为一种微创治疗腰椎间盘突出症(LDH)的方法,在保守治疗和手术干预之间具有广阔的应用前景。自 2018 年在日本获得批准以来,多项单中心试验已经证实了其有效性,然而,LDH 类型、患者年龄、性别等因素对治疗效果的影响仍不清楚。此外,尚未有关于青少年和老年患者的数据报道。在这项回顾性多中心研究中,我们旨在对 Condoliase 治疗 LDH 的成功预后因素进行分类,并评估其对<20 岁和≥70 岁患者的影响。
我们回顾了在日本四家机构接受 Condoliase 治疗的 137 例 LDH 患者的病历,并评估了不同年龄段患者缓解腿部疼痛、腰痛和麻木的视觉模拟量表(VAS)、Oswestry 功能障碍指数(ODI)和日本骨科协会(JOA)评分的疗效。此外,我们将他们分为基线腿部疼痛 VAS 改善≥50%的“组 A”或 VAS 腿部疼痛改善<50%的“组 N”。接下来,我们评估了组 A 和组 N 之间在临床和人口统计学分布上的差异。
55 例患者被分为组 A(77.5%),16 例患者被分为组 N(22.5%)。两组患者的 Pfirrmann 分级存在显著差异,IV 级提示对治疗最敏感。后椎间盘角度>5°也接近统计学意义。在所有年龄组中,平均 VAS 评分均有所改善。然而,75%的青少年患者在治疗后 Pfirrmann 分级恶化。
椎间盘内注射 Condoliase 是治疗 LDH 的有效方法,即使在椎体平移和后椎间盘角度较大的患者中也是如此,且与年龄无关。然而,由于 Condoliase 会增加椎间盘退变的风险,其在年轻患者中的适应证仍存在争议。